The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19잠재적 치료제의 역사, 효능 및 안전성: COVID-19의 복잡한 삶에 대한 서사적 개요Review Published on 2021-01-222022-09-10 Journal: International Journal of Environmental Research an [Category] 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events caused clinical Clinical improvement Clinical studies clinical study conducted convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 effective Efficacy Efficacy and safety evaluate Evidence Favipiravir FIVE history Hydroxychloroquine identify life limitation literature review narrative observational studies pandemic Potential profile public health Randomized controlled trial Randomized controlled trials RCTs Remdesivir reported researcher respiratory Safe Safety SARS-CoV-2 severe acute respiratory syndrome Coronavirus study participation Support the disease Therapeutics therapy Tocilizumab was used were used Withdrawal [DOI] 10.3390/ijerph18030955 PMC 바로가기 [Article Type] Review
A retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipientsOriginal Article Published on 2021-01-222023-06-15 Journal: Transplant infectious disease : an official journa [Category] MERS, SARS, [키워드] COVID‐19 Cytokines outcomes solid organ transplant Tocilizumab [DOI] 10.1111/tid.13556 PMC 바로가기 [Article Type] Original Article
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndromeCOVID-19 관련 사이토카인 방출 증후군 치료에서 IL-6 억제제의 역할Review Published on 2021-01-212022-09-12 Journal: International Journal of Medical Sciences [Category] 진단, [키워드] (Tocilizumab anti-IL-6 appear Case report classical coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients CRS cytokine Cytokine release syndrome described effective Evidence evidence of feature IL-6 IL-6 inhibitor IL-6 inhibitors information inhibiting interleukin interleukin-6 interleukin-6 inhibitor. key factor Pathogenesis pathology patients with COVID-19 rationale role sarilumab severe coronavirus disease severe COVID-19 severe COVID-19 patient severe COVID-19 patients Signaling siltuximab syndrome Therapeutics Tocilizumab trans Treatment triggering [DOI] 10.7150/ijms.53564 PMC 바로가기 [Article Type] Review
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial2019년 중증 또는 중대한 코로나바이러스 질환 환자의 15일째 임상 결과에 대한 토실리주맙의 효과: 무작위 대조 시험Randomized Controlled Trial Published on 2021-01-202022-09-12 Journal: The BMJ [Category] Fulltext, MERS, 임상, 진단, [키워드] 95% confidence interval Adverse age analysed assumption Brazil C reactive protein Clinical outcome clinical status coronavirus disease Critical D dimer death determine died Effect enrolled event ferritin Follow-up hospital IMPROVE lactate dehydrogenase mechanical ventilation men Mortality NCT04403685 occurred Odds ratio open label outcome Patient Primary outcome proportionality randomised controlled trial receive receiving reported serum biomarker Seven single intravenous infusion standard care standard care group supplemental oxygen Tocilizumab Trial [DOI] 10.1136/bmj.n84 PMC 바로가기 [Article Type] Randomized Controlled Trial
Subcutaneous emphysema and pneumomediastinum in patients with COVID-19 disease; case series from a tertiary care hospital in PakistanOriginal Paper Published on 2021-01-202022-11-01 Journal: Epidemiology and Infection [Category] COVID-19, MERS, [키워드] acute respiratory distress Admission age assisted ventilation average Care case sery Chest clinical symptom Complication Convalescent plasma therapy coronavirus disease Corticosteroid cough COVID patient COVID-19 COVID-19 ARDS patients Critically ill Dyspnoea emphysema Fever highest hospital Hospital stay incidence Inflammatory response initial interquartile range Invasive mechanical ventilation lung damage lung disorder median men non-invasive ventilation non-survivor outcome PaO Patient patients died patients of COVID-19 patients with COVID-19 PEEP Pneumomediastinum Positive end-expiratory pressure positive pressure ventilation Seven subcutaneous emphysema survivor Symptom syndrome the patient Tocilizumab triggered [DOI] 10.1017/S095026882100011X PMC 바로가기 [Article Type] Original Paper
Perceptions of Romanian Physicians on Lockdowns for COVID-19 PreventionArticle Published on 2021-01-182022-10-31 Journal: International journal for equity in health [Category] COVID-19, [키워드] acute respiratory syndrome approach catch change clinical picture contrary convalescent plasma coronavirus COVID-19 COVID-19 patients COVID-19 vaccine diagnostic disease effective Efficiency Healthcare systems Hydroxychloroquine initial Intention involved limit literature review lockdown measure Measures MOST oseltamivir pandemic Perception physician physicians’ perception prevention Protective questionnaire Registered rejection remained Romania SARS-CoV-2 SARS-CoV-2 treatment significantly Spread survey the disease therapeutic option thought Tocilizumab Treatment triggering Vaccine [DOI] 10.3390/healthcare9010095 PMC 바로가기 [Article Type] Article
Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab토실리주맙으로 중증 COVID-19 폐렴 및 과염증 증후군의 성공적인 치료Case Reports Published on 2021-01-082022-09-12 Journal: BMJ case reports [Category] 진단, [키워드] Confirmed COVID-19 infection Cytokines death distress Escalation global health Hyperinflammatory syndrome IL-6 IL-6 receptor IMPROVE Infection infections invasive medical management monoclonal antibody Non-invasive occur offer onset of symptoms Patient Pneumonia pneumonia (infectious disease) reduce risk secondary haemophagocytic lymphohistiocytosis Severe COVID-19 pneumonia Supportive treatment survival syndrome therapeutic indications therapeutic indications. Tocilizumab treated Treatment Ventilated [DOI] 10.1136/bcr-2020-238210 PMC 바로가기 [Article Type] Case Reports
Anti-IL6 treatment of serious COVID-19 disease A monocentric retrospective experience심각한 COVID-19 질병의 항IL6 치료 단일 중심적 후향적 경험4900 Published on 2021-01-082022-09-12 Journal: Medicine [Category] 진단, [키워드] acting Acute myocardial infarction acute respiratory distress acute respiratory distress syndrome anti-cytokine anti-IL6 ARDS candidate Candidates clinical trial collected data Complication complications control group coronavirus counterproductive COVID-19 COVID-19 pneumonia cytokine determine died discharged disease drug effective eligible event form framework help Hospitalization Hospitalized identify IL6 Infectious complications Inflammation intensive care interleukin-6 Intervention intravenously Intubated lower mortality medium Mortality multi-organ failure Patient Pneumonia Prognosis Pulmonary thromboembolism reducing respiratory complication Respiratory complications respiratory distress Respiratory failure retrospective risk sarilumab serious COVID-19 severe acute respiratory distress syndrome severe respiratory failure single center Standard of care suffered syndrome systemic level Therapies Thromboembolism Tocilizumab treated Treatment [DOI] 10.1097/MD.0000000000023582 PMC 바로가기 [Article Type] 4900
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia코로나19 폐렴으로 입원한 환자의 토실리주맙Randomized Controlled Trial Published on 2021-01-072022-09-11 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단, [키워드] 95% CI 95% confidence interval Alaska antibody assigned black body weight clinical coronavirus disease Coronavirus disease 2019 COVID-19 pneumonia cumulative death died dose Efficacy EMPACTA ethnic group Genentech hazard ratio Hispanic Hospitalized hospitalized patient hospitalized patients hyperinflammation IMPROVE incidence Inclusion intravenously kilogram Latino likelihood log-rank test mechanical ventilation modified intention-to-treat Native occurred outcome Patient patients hospitalized Placebo placebo group Pneumonia Population populations Primary outcome progression Racial randomization Randomly receive receiving receptor reduced safety population Serious Adverse Event Serious Adverse Events Site standard care survival the log-rank test the patient the placebo group time-to-event analysis Tocilizumab treat white [DOI] 10.1056/NEJMoa2030340 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestationsResearch Article Published on 2021-01-062024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] giant cell arteritis polymyalgia rheumatica Real-world study Tocilizumab Visual manifestations [DOI] 10.1186/s13075-020-02377-8 PMC 바로가기 [Article Type] Research Article